Pfizer and NicOx enter licensing deal

3rd March 2006By Staff Writer

French biopharmaceutical firm NicOx has entered into a licensing deal worth over $385 million with Pfizer for ophthalmology technology.

NicOx has given Pfizer exclusive rights, across the entire field of ophthalmology, to use its proprietary nitric oxide-donating technology. Pfizer will make payments of $27.3 million in the first year of the collaboration, and pay milestones in excess of $356.2 million.

Under the new agreement, Pfizer has also agreed to make an equity investment in NicOx, at a 4.9% premium to the company's share price at the time of purchase. This equity purchase is subject to NicOx shareholder approval and will take place during 2006.

"We believe NicOx' nitric oxide-donating technology has the potential to generate promising new drug candidates for a broad range of eye diseases, a number of which currently have no effective treatment," said Martin Mackay, senior vice-president of worldwide research & technology at Pfizer.

In other news, recent results from an ongoing research agreement between the two companies confirmed the effectiveness of a NicOx glaucoma compound, showing it to be better than the reference drug tested in a validated in vivo model of abnormally high intraocular pressure. This collaboration with Pfizer is focused on the development of more effective treatments for glaucoma also using NicOx' proprietary nitric oxide-donating technology.

Weitere Nachrichten :

http://www.finanznachrichten.de/nachrichten-aktien/nicox.asp

 

http://www.nicox.com/update/home_engl.html  

Und ein Medikament in Phase 3

http://www.nicox.com/update/NicOx_2006/NewFiles/...rch%206-9%2006.pdf

 

 

 

 

 

 

 

Nb	Qté	Achat	Vente	Qté	Nb
1	300	6.89	6.90	2811	2
2	250	6.88	6.91	130	1
5	1581	6.87	6.92	270	2
4	4053	6.85	6.93	4000	2
1	13115	6.84	6.94	3426	2
	FMP	-	-

 

Da gab´s ne empfehlung in Amerika      

 

Nb	Qté	Achat	Vente	Qté	Nb
1	950	7.87	7.95	650	1
1	110	7.86	7.98	2669	3
3	818	7.85	7.99	2689	4
2	855	7.84	8.00	5957	5
3	2650	7.83	8.04	1300	2
	FMP

 

21.03.2006 08:07
NicOx to receive up to 288 mln eur from Merck & co in hypertensive drugs deal
PARIS (AFX) - French pharmeuticals developer NicOx SA (Nachrichten) said it will receive an upfront payment of 9.2 mln eur (11.2 mln usd) from Merck&Co Inc (Nachrichten/Aktienkurs) and is eligible for potential further milestone payments of 279 mln eur (340.2 mln usd) under a major new agreement to collaborate on the development of new antihypertensive drugs using NicOx' proprietary nitric oxide-donating technology.

The agreement follows completion of the companies' research collaboration, which has generated promising results, NicOx said.

The French company has the option to co-promote on a fee for detail basis products that result from the agreement to specialist physicians, such as cardiologists, in the US and certain major European countries.

In addition, Merck will pay NicOx industry standard royalties on the sales of all products resulting from the collaboration.

The agreement covers nitric oxide-donating derivatives of several major classes of antihypertensive agents for the treatment of high blood pressure, complications of hypertension, and other cardiovascular and related disorders, NicOx said.

Merck has the exclusive right to develop and commercialize antihypertensives that use NicOx' nitric oxide-donating technology for the treatment of systemic hypertension, it added.

NicOx will continue to be involved in the new research program, which will be focused on identifying lead candidates for development, while Merck will fund and manage all further pre-clinical and clinical development activities following selection of lead compounds.

'We are very pleased to be entering into this new collaboration with NicOx, which aims to address one of the world's leading health problems,' Anthony Ford-Hutchinson, Executive Vice President for Research Medicine at Merck Research Laboratories, said in a statement.

'We believe NicOx' innovative NO-donating technology has the potential to lead to the development of new and improved antihypertensive medicines,' Ford-Hutchinson said.

equitynext@afxnews.com

an


 

Vol. > 2 Millionen

Bollinger obere Begrenzung bei 8,83 euronen  

 

 

 

1998 haben Furchgott und seine Kolegen Ferid Murad und Louis Ignarro den Nobelpreis der Medizin , für die Entdeckung der Eigenschafften des Moleküls , auf die Nerven , erhalten . Louis Ignarro arbeitet bei NICOX .

( Ich habe nur das wichtigste übersetzt ) ( rot markierte ) 

21/03/2006 - 15h26


(Boursier.com) - Toute l'originalité de NicOx
s'appuie sur une technologie unique de
libération d'oxyde nitrique, que le groupe
compte appliquer à des médicaments existants
dans le but de créer de nouvelles entités
chimiques brevetables. NicOx pense que cette
technologie a le potentiel d'améliorer
l'efficacité et/ou le profil de sécurité de
médicaments conventionnels, voire de modifier
leur activité afin de permettre leur utilisation
dans de nouvelles indications thérapeutiques.

L'oxyde nitrique, également connu sous le nom
moins seyant de monoxyde d'azote, est au départ
un composé chimique instable, polluant notoire,
soupçonné de contribuer aux pluies acides et à
la régression de la couche d'ozone
stratosphérique. Industriellement, la substance
était notamment utilisée pour la fabrication de
l'eau forte. Pas très engageant jusqu'ici, et on
comprend que la découverte des propriétés
biologiques essentielles de l'oxyde nitrique ait
tout d'abord provoqué la surprise, sinon
l'incrédulité.

En 1978, un grand savant américain, Robert F.
Furchgott, identifie une substance agissant au
niveau des vaisseaux sanguins. Il poursuit ses
recherches pour en identifier la nature et le
mode d'action. En 1986, il est clairement établi
que la substance en question n'est autre que le
fameux oxyde nitrique. Cette substance joue un
rôle déterminant dans de nombreux processus
biochimiques du corps humain, en agissant comme
messager moléculaire et transmettant des signaux
biochimiques dans de nombreux tissus, du système
cardiovasculaire (propriétés vasodilatatoires
notamment) au système nerveux central, ou encore
système immunitaire.

Au vu du potentiel thérapeutique, la revue
Science couronne l'oxyde nitrique "Molecule of
the Year" en 1992.

En 1998 Furchgott et ses collègues Ferid Murad
et Louis Ignarro se partagent le prestigieux
prix Nobel de médecine pour leur découverte des
propriétés neuromédiatrices de la molécule.

C'est ce même Louis Ignarro qu'on retrouve
aujourd'hui au comité scientifique de la société
NicOx.
G.B.
©2006 Boursier.com